Abstract
Summary: Anticancer immunotherapy, either alone or in combination with other treatment modalities, is already standard in the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) without proven genetic aberrations. For the first time, encouraging data are available from a five-year follow-up of patients in a phase III study in which patients diagnosed with metastatic NSCLC were treated with first-line immunotherapy.